Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Pharmacogenetics and Genomics|June 23, 2010
Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modelingThorsten Lehr, Hans-Guenter Schaefer, Alexander StaabPharmaceutical Research|January 6, 2012
Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteersIñaki F Trocóniz, Katja Boland, Alexander StaabJournal of Clinical Pharmacology|May 29, 2013
A semi-physiological model of amyloid-β biosynthesis and clearance in human cerebrospinal fluid: a tool for alzheimer's disease research and drug developmentKarin G Haug, Alexander Staab, Chantaratsamon Dansirikul, et al.The AAPS Journal|April 8, 2015
Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled DrugsJens Markus Borghardt, Benjamin Weber, Alexander Staab, et al.Journal of Clinical Pharmacology|February 18, 2010
Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patientsSilke Retlich, Vincent Duval, Ulrike Graefe-Mody, et al.British Journal of Clinical Pharmacology|May 6, 2016
Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalationJens Markus Borghardt, Benjamin Weber, Alexander Staab, et al.Clinical Pharmacokinetics|December 17, 2009
Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazoleThorsten Lehr, Alexander Staab, Dirk Trommeshauser, et al.The AAPS Journal|January 16, 2010
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensineThorsten Lehr, Alexander Staab, Dirk Trommeshauser, et al.CPT: Pharmacometrics & Systems Pharmacology|January 26, 2019
Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by AfatinibRonald Niebecker, Hugo Maas, Alexander Staab, et al.Cancer Chemotherapy and Pharmacology|February 14, 2014
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumorsMatthias Freiwald, Ulrike Schmid, Angele Fleury, et al.Pageof 4